“Continuous Planning and Decisions for Retail”

Sector: MedTech
Founded:
2015 (first capitalized in 2019)
First Invested:
2022
Located:
Oxford, UK
Athens, Greece
Website: 
orthoson.com

Profile

Sector
MedTech

Founded
2015 (first capitalized in 2019)

First Invested
2022

Located
Oxford, UK
Athens, Greece

Website
orthoson.com

Spun out of the University of Oxford’s Institute of Biomedical Engineering, OrthoSon is a medical technology company developing an incisionless treatment for low back pain that will restore the function of the degenerated intervertebral disc. This innovative class III medical device is underpinned by a broad patent portfolio and combines precision therapeutic ultrasound nucleoplasty with an injectable in-situ curing hydrogel implant. This minimally invasive alternative to surgery is intended to deliver a disruptively cost-effective and percutaneous day-case treatment to more than 200,000 patients per year currently suffering from persistent, recurrent back pain. 

Rich Simmonds

Rich Simmonds

CEO

Rich brings more than 25 years of Med Tech experience ranging from start-ups to large corporate organisations. Since graduating with a BSc in Physics, he has held commercial leadership and General Management positions, leading teams and commercialising complex medical devices. Notably he has launched a novel device into the US orthopaedics market, taking annual revenue to $30M. He has established then led a new team of 12 based in Shanghai China. Prior to joining OrthoSon Rich led the EMEA business for Terumo’s Pharmaceutical Solutions Division based in Belgium.

Prof. Constantin Coussios FREng

Prof. Constantin Coussios FREng

CTO & Founder

A serial entrepreneur, Constantin is the Director of the Oxford Institute of Biomedical Engineering and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011.  He was the recipient of the 2017 Silver Medal of the UK’s Royal Academy of Engineering for his contributions to the translation of novel medical technologies into clinical practice. In 2008, he co-founded OrganOx Ltd., which developed the world’s first normothermic liver perfusion device for improved organ preservation prior to transplantation (Nature 2018) through to FDA PMA approval in 2021. In 2014, he was the lead academic founder of OxSonics Ltd., which exploits nanobubbles and ultrasound to enhance drug delivery to tumours, currently in clinical trials. In 2019, he was elected a Fellow of the Royal Academy of Engineering.

Looking for funding?

 

Are you a researcher moving out of the lab or

a tech entrepreneur raising your next round?

Work with us

 

Find open work positions

in Big Pi portfolio companies